Last reviewed · How we verify
NCT07143903: Women Power
Normal Delivery : Optimization of Women Power Using Artificial Intelligence
NA trial testing artificial application in Smart Normal Labor in 216 participants. Completed in 25 October 2025.
20 October 2025
Quick facts
| Lead sponsor | Delta University for Science and Technology |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 216 |
| Start date | 28 August 2024 |
| Primary completion | 20 October 2025 |
| Estimated completion | 25 October 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- artificial application
Conditions studied
- Smart Normal Labor — all drugs for Smart Normal Labor →
Sponsor
Delta University for Science and Technology
Who can join
Adults 16 to 50, female only, with Smart Normal Labor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
As the global population continues to rise, the demand for efficient and effective maternal healthcare solutions becomes increasingly urgent. According to the United Nations, the world population is projected to reach approximately 9.7 billion by 2050, with a significant increase in the number of pregnancies and births. This demographic shift underscores the necessity for innovative healthcare technologies that can address the unique challenges faced by expectant mothers during childbirth. The first stage of labor, which involves the onset of contractions and the gradual dilation of the cervix, is a critical period that requires careful monitoring and support. Many women experience anxiety and uncertainty during this time, often exacerbated by a lack of accessible information about labor progression. A lack of information and support during this pivotal time can lead to stress, impacting both maternal well-being and the overall labor experience. To address these challenges, the integration of artificial intelligence (AI) and mobile health technologies offers a transformative opportunity to empower women. Traditional methods of labor monitoring can be resource-intensive and may not provide the real-time insights that mothers need to make informed decisions about their care. In this context, the integration of artificial intelligence (AI) and mobile health technologies presents a transformative opportunity. By developing a mobile application specifically designed to monitor the first stage of labor, we can empower expectant mothers with real-time data and personalized guidance. This application aims to track contractions, analyze symptoms, and provide educational resources, ultimately enhancing the labor experience for women .Furthermore, the application will not only serve individual users but also support healthcare providers by offering valuable insights into patient progress. With data-driven analytics, practitioners can make more informed decisions, allocate resources more efficiently, and improve overall care delivery. This proposal outlines the development and evaluation of an AI-powered labor monitoring application that addresses the challenges posed by a growing population and increasing childbirth rates. By focusing on validity and reliability in our methodology, this project aims to contribute to the evolving field of digital health, promoting better outcomes for mothers and their newborns in an increasingly complex healthcare landscape. By developing a mobile application specifically designed to monitor the first stage of labor, we aim to equip expectant mothers with real-time data and personalized guidance. This application will track contractions, analyze symptoms, and provide educational resources tailored to individual needs. By empowering women with knowledge and insights about their labor progression, the app will foster confidence and enable informed decision-making regarding their care. Furthermore, the application will facilitate communication between expectant mothers and healthcare providers, ensuring that women receive timely support and intervention when necessary. By utilizing predictive analytics, the app can alert users and healthcare professionals to concerning patterns, thus improving responsiveness and care outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07143903
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Delta University for Science and Technology trials
Trials by the same sponsor.
- NCT07321119 — Correlation Between Cervical Deep Flexors Endurance and Proprioception Function in Cervical Radiculopathy · not yet recruiting
- NCT07289607 — Effect of TECAR on Cervical Radiculopathy · NA · not yet recruiting
- NCT07292675 — The Effect of Low Intensity With BFR on Stroke Patients · NA · not yet recruiting
- NCT07230938 — Effects of Neck Proprioception Impairment on Balance in Cervical Spondylosis Patients · not yet recruiting
- NCT07333872 — Evaluation of Pulpotomy, Partial Pulpotomy, and Direct Pulp Capping Using Mineral Trioxide Aggregate. · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07143903 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Delta University for Science and Technology
- Last refreshed: 20 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07143903.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing